Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

toripalimab 5tislelizumab 3pembrolizumab 3spartalizumab 2camrelizumab 2Paclitaxel 2Injections 2Immune Checkpoint Inhibitors 2Drug Therapy 2sintilimab 1serabelisib 1sapanisertib 1penpulimab 1olaparib 1lenvatinib 1fludarabine 1conteltinib 1atezolizumab 1anlotinib 1adagrasib 1Sorafenib 1Sirolimus 1Oxaliplatin 1Metformin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Irinotecan 1Inosine 1Immunotherapy 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Solid Tumor × Inosine × Clear all
NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Beijing Friendship Hospital

Phase 2/3 Completed
172 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡